| Dr Tamara C Medley, MD | |
|
1075 Sw Grandview Avenue, Ste 200, Grants Pass, OR 97527 | |
| (541) 479-8363 | |
| (541) 476-2841 |
| Full Name | Dr Tamara C Medley |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 26 Years |
| Location | 1075 Sw Grandview Avenue, Grants Pass, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053314377 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD23689 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asante Three Rivers Medical Center | Grants pass, OR | Hospital |
| Asante Rogue Regional Medical Center | Medford, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Women's Health Center Of Southern Oregon Pc | 8628041720 | 15 |
News Archive
Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round.
Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.
Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.
› Verified 1 days ago
| Entity Name | Women's Health Center Of Southern Oregon Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528175437 PECOS PAC ID: 8628041720 Enrollment ID: O20040817000751 |
News Archive
Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round.
Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.
Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tamara C Medley, MD 1075 Sw Grandview Avenue, Ste. 200, Grants Pass, OR 97527 Ph: (541) 479-8363 | Dr Tamara C Medley, MD 1075 Sw Grandview Avenue, Ste 200, Grants Pass, OR 97527 Ph: (541) 479-8363 |
News Archive
Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round.
Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.
Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.
› Verified 1 days ago
Dr. Raymond Gambrill, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1075 Sw Grandview Ave, Ste 200, Grants Pass, OR 97527 Phone: 541-479-8363 Fax: 541-476-2841 | |
Dr. Felicia Cohen, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1075 Sw Grandview Avenue, Ste 200, Grants Pass, OR 97527 Phone: 541-479-8363 Fax: 541-476-2841 | |
Thomas Eagan, D.O, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1075 Sw Grandview Avenue, Ste. 200, Grants Pass, OR 97527 Phone: 541-479-8363 Fax: 541-476-2841 | |
Caroline Lansing Kelly, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1075 Grandview Ave Ste 200, Grants Pass, OR 97527 Phone: 541-479-8363 Fax: 541-476-2841 |